Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks Additional ENDO highlights inc
SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced new long-term data from its clinical development program evaluating novel PALSONIFYTM (paltusotine) in acromegaly during an oral presentation at the Endocrine Society’s Annual Meeting, ENDO 2026. Notably, pooled data from the open-label extension (OLE) trials of PATHFNDR-1 and PATHFNDR-2 show that after two years of treatment, PALSONIFY was effective and well-tolerated in patients who were switched from standard-of-care monthly injectable somatostatin receptor ligands (SRLs) and those who were medically untreated, respectively, when oral, once-daily PALSONIFY was initiated.
Read More
Đọc thêm từ Tài chính
Not just for the super rich: 8 in 10 DBS retail customers get dedicated wealth planning managers
The number of customers who “upgraded” to the DBS Treasures segment also rose 130% year on year in the first quarter.
The business of the beautiful game
Once viewed as entertainment, football is increasingly being treated as an investable asset class.
Will the real Kevin Warsh please stand up? Ahead of his first Fed meeting, economists honestly don’t know what to expect.
Perhaps the only thing that can be said with certainty about Kevin Warsh’s press conference following his first meeting as Federal Reserve chair this week is that he will have a captive audience.
askST Jobs: Will AI make it harder for young workers to learn on the job?
AI is changing how young workers learn, shifting the focus from routine tasks to decision-making.